Vistagen Therapeutics (VTGN) Enterprise Value (2017 - 2025)
Historic Enterprise Value for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$61.8 million.
- Vistagen Therapeutics' Enterprise Value rose 3025.07% to -$61.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$61.8 million, marking a year-over-year increase of 3025.07%. This contributed to the annual value of -$80.5 million for FY2025, which is 3246.23% up from last year.
- Vistagen Therapeutics' Enterprise Value amounted to -$61.8 million in Q4 2025, which was up 3025.07% from -$77.2 million recorded in Q3 2025.
- In the past 5 years, Vistagen Therapeutics' Enterprise Value registered a high of -$9.6 million during Q2 2023, and its lowest value of -$126.6 million during Q4 2023.
- For the 5-year period, Vistagen Therapeutics' Enterprise Value averaged around -$72.3 million, with its median value being -$78.8 million (2025).
- In the last 5 years, Vistagen Therapeutics' Enterprise Value crashed by 750890.71% in 2021 and then soared by 8149.56% in 2023.
- Over the past 5 years, Vistagen Therapeutics' Enterprise Value (Quarter) stood at -$83.7 million in 2021, then soared by 70.09% to -$25.0 million in 2022, then tumbled by 405.65% to -$126.6 million in 2023, then soared by 30.05% to -$88.6 million in 2024, then soared by 30.25% to -$61.8 million in 2025.
- Its last three reported values are -$61.8 million in Q4 2025, -$77.2 million for Q3 2025, and -$63.2 million during Q2 2025.